NR-601 Week 7 turns the whole medicine list into the clinical problem. The territory is polypharmacy and deprescribing: reconciling what the patient actually takes against what the chart claims, finding the agent that is treating a side effect of another agent, and writing a staged withdrawal plan with monitoring attached. Your section may print this as NR 601 or NR601; it is the same course. Chamberlain publishes no syllabi outside Canvas. The placement here is our teaching judgment from the course's catalog arc; your section's rubric decides what your week actually asks.
By week seven of an eight-week session the case work usually expects you to reason across every condition at once instead of one at a time, which is exactly what a medicine list forces. The boundary this desk keeps: we write and revise the paper. Any change to a real patient's regimen belongs to you, your preceptor and your state's prescribing rules.
What NR-601 Week 7 asks for
Expect the territory to cover reconciliation as an active process rather than a transcription, age-related changes in absorption, distribution, metabolism and clearance, potentially inappropriate agents in older adults and the published criteria that flag them, anticholinergic and sedative burden added up across the whole list, prescribing cascades, dose adjustment for kidney and liver function, adherence realities including cost, dexterity and vision, and the deprescribing sequence itself with tapering and monitoring built in.
The written shapes at this stage are usually a full medication review for one older patient with a long list, a deprescribing plan for one or two specific agents with the reasoning defended, or a case where an adverse effect is traced back through the list to its source. If your section runs a discussion this week, it often asks which one agent you would stop first and how you would explain it to the patient.
The scoring divide is the difference between listing and reviewing. Reprinting the regimen with doses earns almost nothing; giving every agent an indication, a benefit horizon and a verdict earns the row.
The NR-601 Week 7 method, step by step
Six moves that turn a fourteen-item list into a defended plan.
-
Reconcile against the bottles, not the chart
Ask what is actually taken, when, and at what dose, including over the counter products, supplements, eye drops, topicals and anything borrowed. Discrepancies between the chart and the reality are findings, and the paper should report them as such.
-
Give every agent an indication and a horizon
Why it was started, by whom, when, and how long before its benefit is realized. Agents with no traceable indication and agents whose benefit arrives after this patient's realistic horizon are the two categories that generate most of the paper's recommendations.
-
Add up the burden across classes
Anticholinergic and sedative effects accumulate from agents that look unrelated on the page. Total the burden rather than judging each item alone, because the risk that matters is the sum the patient is carrying.
-
Look for the cascade
Trace each symptom-treating agent back to the agent that may have caused the symptom. Finding one cascade and writing it out is often the strongest single paragraph in this week's paper, because it shows reasoning across the whole list.
-
Rank what comes off and stage it
One or two agents at a time, highest risk and lowest benefit first, with a taper where withdrawal is a real risk. Say what you expect to happen, what would count as trouble, and what you would do if it appeared.
-
Write the conversation, not just the decision
How you would explain the change to a patient who has taken the agent for years, what you would agree to monitor together, and the follow-up date. Then format: current APA, headings in your rubric's wording, doses and units checked line by line.
A medication review, section by section
Targets assume a review near 1,500 words. Rescale to your prompt, and expect the verdict table and the plan to carry most of the weight whatever the total.
| Section | What belongs there | Word target |
|---|---|---|
| Patient and reconciliation findings | Conditions, kidney and liver function, and every discrepancy between the chart and what is taken | 230 to 280 |
| Agent by agent verdict | Each item with indication, prescriber, start date where known, benefit horizon and a keep, change or stop verdict | 380 to 450 |
| Burden and interaction analysis | Anticholinergic and sedative totals, interactions found, and dose adjustments the organ function requires | 260 to 320 |
| Cascade traced | At least one symptom-treating agent followed back to its probable cause, with the evidence | 190 to 230 |
| Deprescribing plan | What comes off first, in what order, tapered how, monitored for what, over what period | 300 to 360 |
| Patient conversation and follow-up | How the change is explained, what the patient agreed to watch, and the recheck date | 180 to 220 |
If your verdict section reaches the end of the list without a single stop or change, either the patient has an unusually clean regimen or the review has not happened yet. Say which, and defend it.
Citing prescribing guidance for older adults
Published criteria for potentially inappropriate medicines in older adults are consensus documents that get revised, so cite the current edition, name the issuing body, and put the year inside your sentence. A criterion quoted from an older version can be flatly wrong now, and graders in this territory check.
Distinguish flagged from forbidden. Criteria identify agents that warrant caution and a documented rationale in most older adults, not agents that are banned. The strongest papers state the flag, then argue this patient's case either way, which is more useful clinically and more impressive academically than mechanical removal of everything on a list.
Handle deprescribing evidence carefully. Withdrawal studies are often small, specific to one class and measured over short windows, so give the design, the sample and the follow-up period, and keep the verb honest: randomized withdrawal supports no increase in events; observational work supports was associated with. Where a professional body publishes current tapering guidance for the class you are stopping, cite that current edition with its year in your prose.
Five mistakes that cost points in a medicine week
- The list reprinted rather than reviewed. Doses and frequencies with no indication, no horizon and no verdict is transcription.
- Supplements and over the counter products omitted. Some of the most consequential interactions in this population never appear in the chart.
- Burden judged one agent at a time. Three mildly sedating items are a sedation problem even when each looks acceptable alone.
- Deprescribing without a taper or a watch plan. Stopping is an intervention, and it needs monitoring like any other.
- Criteria applied mechanically. Removing everything flagged, with no argument about this patient, misses the judgment the row is scoring.
Before you submit
- Reconciliation reports what the patient takes, not what the chart lists
- Every agent carries an indication, a benefit horizon and a verdict
- Anticholinergic and sedative burden is totaled across the whole list
- At least one prescribing cascade is traced with its evidence
- The deprescribing plan names order, taper, monitoring and duration
- Every criterion cited names its issuing body and its current edition year
Medication review due this week?
Send the prompt and the rubric from Canvas. An original draft returns inside 24 to 48 hours with every agent given a verdict and the taper plan written out.